Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-29T09:36:10.034Z Has data issue: false hasContentIssue false
  • English
  • Français

A Clinical Audit on the Monitoring and Management of Antipsychotic-Induced Hyper Prolactinaemia

Published online by Cambridge University Press:  01 August 2024

Noman Khan
Noman Khan*
Affiliation:
South West Yorkshire Foundation Trust, Yorkshire, United Kingdom
*
*Presenting author.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims

Antipsychotic medications are one of the major iatrogenic causes of hyperprolactinaemia with the attendant short- and long-term effects and risks associated with it.

  • • The audit sought to answer the question: Are we monitoring and managing hyper prolactinemia caused by anti psychotic medications appropriately?

Methods

  • • A literature search for relevant data and standards with regards to monitoring and management of hyperprolactinaemia was conducted.

  • • The audit was based on the standards derived from South West Yorkshire NHS Partnership Foundation Trust’s (SWYPFT) standards, NICE guidelines, and the Maudsley Prescribing Guidelines in Psychiatry (14th edition), focusing on the Trust's standards.

  • • The total population under consideration included every patient under the care of the North Kirklees, Community mental health team (CMHT), Old age psychiatry services (OPS) that was using antipsychotic medication in the time period between 16 June 2022 and 15th July 2023.

Results

  • • Total patients 61

  • • Female 30

  • • Male 31

  • • Age: 65 and above

  • • Already on antipsychotic: 49

  • • Started on antipsychotic: 12

  • • Two or more antipsychotic: 2

  • • Switch from one antipsychotic to other: 4

  • • Prolactin monitoring not required: 27 because were already using olanzapine, quetiapine and aripiprazole

Monitoring required: 34

  • • Initiation: 12

  • • Prolactin level done 2/12

  • • Prolactin level not done 10/12

  • • LAI (long acting antipsychotic) 11

    Prolactin level done 7/11

    Prolactin level not done 4/12

    Not done: 75% were with Care coordinator

    25% Wellbeing team

  • • On oral antipsychotic that require prolactin level monitoring: 11

  • • Prolactin level done 5/11

  • • Prolactin level not done 6/11

Conclusion

Patients who were on antipsychotics in community required prolactin monitoring. In more than 50% of patients prolactin were not monitored regularly because of communication gap between Psychiatrist and GPs as no clear instructions were mentioned from Psychiatrist to GPs, patients and care coordinators.

A small number of patients in whom prolactin was raised were highlighted to their respective medics and managed accordingly.

Type
5 Audit
Information
BJPsych Open , Volume 10 , Supplement S1: Abstracts from the RCPsych International Congress 2024, 17–20 June , June 2024 , pp. S243
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Footnotes

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard BJPsych Open peer review process and should not be quoted as peer-reviewed by BJPsych Open in any subsequent publication.

Submit a response

eLetters

No eLetters have been published for this article.